trial summary · NCT06807021
Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients
Post-operative Topical Administration of Fibrosis Inhibiting Compound FS2 in a Double- Blind, Randomized, Vehicle-controlled Study Evaluating the Safety and Mitigation of Cutaneous Scarring in Skin Graft and Donor Sites in Burn Patients
Trial record from the TrialBase DB dataset, status RECRUITING, condition Burn Scar, sponsored by Birch BioMed Inc. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The goal of this study is to see how an ingredient called kynurenic acid (which we named "FS2") affects scar formation in people with burn injuries that need skin graft surgery. A cream with FS2 will be used on both the area where the skin graft was placed and the area where the skin was taken (donor site). The cream will be applied after the skin has healed. This study will help us understand if FS2 is safe and effective for mitigating skin scar formation in burn patients.
Source record: https://clinicaltrials.gov/study/NCT06807021
Facts
| registry id | NCT06807021 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2/PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Burn Scar |
| sponsor | Birch BioMed Inc |
| sponsor class | INDUSTRY |
| enrollment | 70 |
| start date | 2027-03 |
| primary completion | 2027-09 |
| completion | 2027-09 |
| results posted | not reported |
Conditions
- Burn Scar
- Burn Wound
Interventions
- IP1 control cream (Vehicle base)
- IP2 - 0.5% w/w FS2
Countries
- Canada
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.